Impact of aetiology of mitral regurgitation on outcome after Mitraclip: lessons learned from MitraSwiss Registry.
Daniel Sürder1; Catherine Klersy2; Roberto Corti3; Luigi Biasco4; Oliver Gaemperli3; Francesco Maisano5; Stefan Toggweiler6; Raban Jeger7; Barbara Naegeli8; Stephane Noble9; Patric Biaggi3; Tiziano Moccetti10; Giovanni Pedrazzini11, Head of Cardiology; Moreno Curti2; Igal Moarof12; Olivier Mueller13;
1. Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland 2. Service of Clinical Epidemiology & Biometry, Policlinico San Matteo, Pavia, Italy 3. Division of Cardiology, Hirslanden Klinik, Zurich, Switzerland 4. Department of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Italy; Division of Cardiology, Azienda Sanitaria Locale TO 4, Ciriè, Italy 5. Division of Cardiovascular Surgery, University Hospital Zürich, Switzerland 6. Division of Cardiology, Kantonsspital Luzern, Switzerland 7. Division of Cardiology, University Hospital Basel, Switzerland 8. Division of Cardiology, Klinik Im Park, Zürich, Switzerland 9. Division of Cardiology, University Hospital Geneve, Switzerland 10. Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland; Department of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Italy 11. Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland; Department of Biomedical Sciences, Universita della Svizzera Italiana, Lugano, Italy, Switzerland 12. Division of Cardiology, Kantonsspital Aarau, Switzerland 13. Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
Aims: The Swiss national registry on percutaneous mitral valve interventions was established in 2011 to monitor safety/ efficacy of percutaneous mitral valve repair (PMVR) with MitraClip. We report in-hospital, short and mid-term outcomes of all patients prospectively enrolled.
Methods and results: Since 2011, MitraSwiss enrolled 1212 patients with moderate and severe MR of functional (FMR) or degenerative (DMR) etiology treated with PMVR in 10 centers. Pre-specified endpoints included clinical, echocardiographic and functional parameters with follow up planned up to 5 years. Outcomes are compared according to MR etiology. Acute procedural success was achieved in 91.5% of cases, with no differences between FMR and DMR and sustained good mid-term results. NYHA class and pulmonary pressure improved significantly in both cohorts. Cumulative probability of death at 5 years was 54% (95%CI 45-63) in FMR and 45% (95%CI 37-54) in the DMR (HR=1.15, p=0.009). Age, anemia, impaired renal function and reduced left ventricular ejection fraction resulted as independent predictors of death at 5 years.
Conclusions: In a large contemporary cohort of non-surgical patients with severe MR, PMVR confirms its safety and effectiveness. At a mid-term follow up mortality and MACE are lower in DMR patients, though MR aetiology is not directly and independently associated with outcome.